The high expression of c-MYC/MYCN target genes indicative of poor prognostic value in developing sympathoblasts suggests that targeting NB such as this cell population may present a novel treatment strategy for treating some of the worst outcome cases. The gene discussed is MYCN; the disease is neuroblastoma.